The formation of new neurons (neurogenesis) in the adult brain, primarily in the Hippocampus (dentate gyrus) and subventricular zone, which continues throughout life in response to specific inflammatory and trophic signals. This process requires a precise inflammatory threshold: moderate chronic low-grade inflammation (metaflammation) promotes neural stem cell proliferation and differentiation, while both absent inflammation and excessive chronic inflammation (CRP >5 mg/L) suppress it, creating a U-shaped dose-response relationship.
Think of building a new neighbourhood in a city. You need construction crews (inflammatory cytokines like IL-6), building materials (glucose, amino acids), architects (neurotrophic factors like BDNF), and safety inspectors (microglia). A moderate level of construction activity—a few crews working steadily—keeps the neighbourhood growing and adapting. This is healthy metaflammation: IL-6 arrives like a foreman, signals "we need more workers here," triggers energy delivery, and simultaneously lays down scaffolding for new neurons.
But if there's NO construction activity (immune suppression), the neighbourhood stagnates—no new homes, no adaptation to changing needs. Conversely, if there's a full-blown demolition and reconstruction site everywhere (CRP >5 mg/L, chronic high inflammation), the chaos prevents any organised building. Debris piles up, resources are diverted to damage control, and new construction grinds to a halt. The foreman (IL-6) is now screaming orders, but no one can hear the blueprint instructions (BDNF signals get drowned out). The hippocampus—your memory and emotional regulation district—stops growing new buildings, and cognitive function declines.
Neuroneogenesis occurs through a tightly regulated cascade involving inflammatory cytokines, neurotrophic factors, and metabolic signals:
graph TD
A["Moderate inflammation<br/>IL-6 2-10 pg/mL"] --> B["IL-6 binds IL-6R<br/>+ gp130 complex"]
B --> C[JAK-STAT3 activation]
C --> D[STAT3 nuclear translocation]
D --> E[BDNF gene transcription]
E --> F[BDNF secretion]
F --> G["BDNF binds TrkB receptor<br/>on neural stem cells"]
G --> H[PI3K-Akt pathway activation]
H --> I[mTOR activation]
I --> J[Protein synthesis]
J --> K["Neural stem cell<br/>proliferation & differentiation"]
L["High inflammation<br/>CRP >5 mg/L"] --> M["TNF-α + IL-1β elevation"]
M --> N["NF-κB hyperactivation"]
N --> O[Microglial M1 polarization]
O --> P["Oxidative stress<br/>ROS/RNS production"]
P --> Q[BDNF suppression]
Q --> R[Neuroneogenesis BLOCKED]
S["Low inflammation<br/>IL-6 <1 pg/mL"] --> T[Insufficient trophic signaling]
T --> R
Detailed molecular cascade for optimal neuroneogenesis:
-
Inflammatory priming (optimal range):
- IL-6 (2-10 pg/mL) → IL-6R + gp130 heterodimerization → JAK1/2 phosphorylation → STAT3 phosphorylation (Tyr705)
- Parallel: IL-6 → MAPK-ERK1/2 pathway → CREB phosphorylation
-
Neurotrophic factor induction:
- pSTAT3 → nucleus → BDNF promoter binding → BDNF transcription
- pCREB → CRE sites on BDNF exon IV → BDNF mRNA production
- BDNF translation → proBDNF → mature BDNF (cleaved by tissue plasminogen activator)
-
Neural stem cell activation (dentate gyrus subgranular zone):
- BDNF → TrkA Receptor (high-affinity) → receptor dimerization
- TrkA → PI3K → PIP2 → PIP3 → PDK1 → Akt phosphorylation
- Akt → mTORC1 activation → S6K + 4E-BP1 phosphorylation → ribosomal protein synthesis
- Parallel: TrkA → PLCγ → IP3/DAG → Ca²⁺ release → CaMKII → CREB → immediate early genes (c-Fos, Arc)
-
Proliferation markers:
- Neural stem cells (GFAP+/nestin+) → transit-amplifying cells (Tbr2+) → immature neurons (doublecortin/DCX+) → mature granule neurons (NeuN+)
- Timeline: proliferation (days 1-7) → migration (days 7-14) → differentiation (weeks 2-4) → integration (weeks 4-8)
-
Metabolic support:
- IL-6 → hypothalamus → increased glucose uptake → GLUT1/GLUT4 upregulation in hippocampus
- Ketone bodies (β-hydroxybutyrate) → HDAC inhibition → BDNF promoter acetylation → enhanced transcription
- Lactate (from astrocytes) → MCT2 transport into neurons → pyruvate → NAD+ → sirtuin activation → PGC-1α → mitochondrial biogenesis
Inhibitory cascade (high inflammation):
- CRP >5 mg/L → complement activation → C5a → microglial TLR4 priming
- TNF-α >20 pg/mL + IL-1β >5 pg/mL → NF-κB (p65/p50) nuclear translocation → iNOS + COX-2 expression
- NO + O2⁻ → peroxynitrite (ONOO⁻) → protein nitration → BDNF oxidative degradation
- TNF-α → TNFR1 → ceramide production → mitochondrial dysfunction → neural stem cell apoptosis
- Microglial M1 phenotype → glutamate release → NMDA receptor overactivation → excitotoxicity
Neuroneogenesis is central to treatment-resistant depression, cognitive decline, PTSD recovery, and neurodegenerative disease prevention. The U-shaped inflammation curve explains why both anti-inflammatory excess (NSAIDs, corticosteroids) and chronic inflammation (obesity, chronic infection, autoimmune disease) impair hippocampal function.
Metamodel connections:
- Metamodel 1 (Evolution): Human brain size expansion required sustained metaflammation for neuroplasticity—complete immune suppression was never evolutionarily viable
- Metamodel 3 (Selfish Brain): The brain prioritises glucose/ketones for neuroneogenesis over peripheral tissues during metabolic stress
- Metamodel 5 (Intermittent Living): Exercise-induced IL-6 pulses (10-100× baseline) drive BDNF surges without chronic elevation
Clinical thresholds:
- Optimal IL-6: 2-10 pg/mL (promotes neuroneogenesis)
- CRP threshold: >5 mg/L marks transition to neurotoxic inflammation
- BDNF serum levels: <10 ng/mL associated with depression; >20 ng/mL protective
- Cortisol: Chronic elevation (>25 μg/dL morning) suppresses hippocampal neurogenesis via glucocorticoid receptor-mediated BDNF repression
Patient populations:
- Major depressive disorder: Hippocampal volume loss correlates with failed neuroneogenesis; SSRIs work partly by restoring BDNF
- Alzheimer's prevention: Neuroneogenesis maintains cognitive reserve; exercise + omega-3s optimise the inflammation window
- PTSD: Impaired hippocampal neurogenesis prevents fear extinction; trauma-focused therapy + metabolic support required
- Inflammatory bowel disease + depression comorbidity: Peripheral IL-6 crosses blood-brain barrier via circumventricular organs, driving both hippocampal BDNF and inflammatory overshoot
Intervention strategy:
- Optimise metaflammation: Resistance training (IL-6 pulses without chronic elevation), omega-3s (EPA/DHA shift lipoxins to pro-resolving)
- Support BDNF directly: Aerobic exercise (increases hippocampal BDNF 2-3×), intermittent fasting (β-hydroxybutyrate), magnesium (NMDA receptor co-factor)
- Reduce neuroinflammation: Resolve gut dysbiosis (LPS translocation drives systemic TNF-α), manage chronic infections, SPMs (resolvins/maresins)
- Monitor biomarkers: CRP, IL-6, BDNF (research settings), HbA1c (insulin resistance impairs hippocampal glucose metabolism)
Clinical red flags:
- Patient on chronic NSAIDs + antidepressants → may need NSAID tapering to restore healing inflammation
- Obesity (BMI >30) + CRP >10 mg/L + depression → metaflammation has shifted to pathological; address insulin resistance first
- Post-viral fatigue + cognitive fog → check for persistent immune activation (ferritin, IL-6); support resolution pathways
- Neuroneogenesis occurs primarily in the dentate gyrus of the hippocampus (memory formation) and subventricular zone (olfactory function, executive control)
- IL-6 optimal range: 2-10 pg/mL promotes BDNF expression; <1 pg/mL insufficient trophic signaling; >20 pg/mL switches to neurotoxic
- CRP >5 mg/L threshold: marks transition from beneficial metaflammation to destructive neuroinflammation; suppresses hippocampal cell proliferation by 40-60%
- BDNF Val66Met polymorphism: ~30% of population; Met allele reduces activity-dependent BDNF secretion, requiring higher exercise intensity for neurogenesis
- Timeline: Neural stem cell → transit-amplifying cell (1 week) → immature neuron (2-3 weeks) → functionally integrated neuron (4-8 weeks); antidepressant efficacy aligns with this timeline
- Depression and hippocampal volume: Untreated major depression shows 8-10% hippocampal volume reduction; correlates with failed neuroneogenesis, not just atrophy
- Exercise dose-response: Aerobic exercise increases hippocampal BDNF 2-3× baseline; resistance training increases systemic IL-6 10-100× during session (transient pulse)
- Interferon-alpha therapy: Used for hepatitis C; causes depression in 30-50% of patients via hippocampal neurogenesis suppression (experimental proof in humans)
- Neurogenesis markers: BrdU (research), DCX (doublecortin immunostaining), Ki-67 (proliferation marker); clinical proxies include hippocampal volume on MRI, cognitive testing
- Ketone bodies: β-hydroxybutyrate (0.5-3 mM) acts as HDAC inhibitor → opens BDNF promoter chromatin → enhances transcription; mechanism for ketogenic diet neuroprotection
- Microglial phenotype: M2 microglia (anti-inflammatory) support neurogenesis via IGF-1, BDNF secretion; M1 microglia (pro-inflammatory) release TNF-α, IL-1β, ROS → block proliferation
- IL-6 — primary cytokine driving neuroneogenesis at 2-10 pg/mL via JAK-STAT3 → BDNF transcription; dual role as energy sensor and neurotrophic signal
- BDNF — master neurotrophic factor; binds TrkA Receptor on neural stem cells → PI3K-Akt-mTOR pathway → protein synthesis and differentiation
- C-reactive protein — CRP >5 mg/L threshold marks shift from beneficial metaflammation to neurotoxic inflammation; suppresses hippocampal cell division
- chronic low-grade inflammation — metaflammation provides optimal signaling environment for neurogenesis; complete absence or excess both impair it
- Hippocampus — primary site of adult neuroneogenesis in dentate gyrus subgranular zone; critical for memory consolidation and emotional regulation
- Depression — failed hippocampal neurogenesis central to pathophysiology; SSRIs require 4-8 weeks (neurogenesis timeline) for efficacy
- treatment-resistant depression — may involve inflammatory overshoot (CRP >10 mg/L) blocking BDNF signaling; anti-TNF biologics show promise in subset
- anterior cingulate cortex — receives projections from hippocampal neurogenesis; involved in emotion regulation and cognitive control affected by impaired neurogenesis
- neuroplasticity — neuroneogenesis is one form of structural neuroplasticity; others include synaptogenesis, dendritic spine remodeling, myelination
- Allopregnanolone — neurosteroid that enhances GABA-A receptor function and promotes neurogenesis; "master of neuroneogenesis" via GABA-mediated calcium signaling
- TNF-α — at >20 pg/mL, drives M1 microglial polarization → oxidative stress → BDNF degradation; blocks neurogenesis in high inflammation states
- Interleukin-1 — IL-1β >5 pg/mL activates NF-κB → iNOS expression → nitric oxide → peroxynitrite → neural stem cell apoptosis
- Exercise — resistance training creates transient IL-6 pulses (10-100× baseline) without chronic elevation; aerobic exercise increases hippocampal BDNF 2-3×
- cognitive decline — reduced neurogenesis contributes to age-related memory loss; interventions targeting metaflammation and BDNF slow decline
- chronic inflammation — sustained CRP >10 mg/L, TNF-α >30 pg/mL create hostile microenvironment for neural stem cells; seen in obesity, autoimmune disease
- immune suppression — chronic corticosteroids, NSAIDs suppress IL-6 below threshold needed for BDNF induction; paradoxically impair brain repair
- Insulin resistance — impairs hippocampal glucose metabolism via reduced GLUT4 translocation; insulin receptor signaling also directly supports neurogenesis
- beta-hydroxybutyrate — ketone body (0.5-3 mM) acts as HDAC inhibitor → BDNF promoter acetylation → enhanced transcription; neuroprotective in fasting/ketogenic diet
- mTOR — mechanistic target of rapamycin; activated by Akt downstream of BDNF-TrkA signaling; drives ribosomal protein synthesis required for neuron maturation
- microglia — M2 phenotype secretes IGF-1, BDNF to support neurogenesis; M1 phenotype releases TNF-α, ROS to block it; phenotype determined by inflammation level
- PTSD — failed hippocampal neurogenesis impairs fear extinction and contextual memory processing; trauma-focused therapy + metabolic support restores it
- omega-3 fatty acids — EPA/DHA reduce TNF-α, increase resolvins → shift inflammation curve leftward; maintain metaflammation sweet spot for neurogenesis
- intermittent fasting — elevates β-hydroxybutyrate, induces transient stress response → BDNF upregulation; hormetic signal for brain adaptation
- TrkA Receptor — high-affinity BDNF receptor on neural stem cells; initiates PI3K-Akt and PLCγ-Ca²⁺ cascades driving proliferation and differentiation